LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Healthineers Strategy 2025 to Focus on AI

By LabMedica International staff writers
Posted on 18 Jan 2018
Siemens Healthineers (Erlangen, Germany) has laid out its strategy to bolster its market leadership by 2025 and beyond, aimed at accelerating profitable growth and delivering return. The company has stated that it is well prepared to take advantage of the paradigm shift and structural growth opportunities in healthcare.

Siemens Healthineers estimates its core markets to grow by 3-5% annually on average from 2016 to 2021 to more than €50 billion per year, driven by growing and aging population, rise in chronic diseases, and improved access to healthcare in the emerging markets. With healthcare productivity historically lagging behind that of the other industries, the industry is witnessing horizontal and vertical consolidation, and governments and insurers are changing the financial incentive systems to transform healthcare delivery from volume to value. Additionally, medicine is becoming more precise and accessible, thereby empowering patients.

Digitalization and the use of artificial intelligence is further driving these changes in healthcare. Big data is becoming a source of value creation in the sector due to its abundant availability. Siemens Healthineers believes that it is well positioned to capitalize on the opportunities being created in the market due to its strong market position across the continuum of care. The company aims to drive profitable growth in its core business further and has a roadmap to its improve future profitability. Siemens Healthineers' Strategy 2025 is focused specifically on five future-oriented areas:

• Utilizing its unique position in the in-vivo and in-vitro markets to combine data and knowledge around precision medicine and make it relevant for clinical use

• Using data and artificial intelligence to integrate existing and innovative technologies for therapy

• Coordinating and optimizing the patient journey through the healthcare continuum

• Developing a full range of technical, operational and clinical service offerings that are more effective and more efficient by using technologies from Siemens Healthineers

• Continuing to develop and invest in capabilities in artificial intelligence that support the above areas

Siemens AG is preparing to list Siemens Healthineers on the Prime Standard segment of the Frankfurt Stock Exchange's Regulated Market during the first half of calendar year 2018.

"It is a pleasure to talk about Siemens Healthineers, a business well prepared to take advantage of the paradigm shifts in healthcare," said Michael Sen. Chairman of the Supervisory Board of Siemens Healthineers and member of the Siemens Managing Board also responsible for the company's healthcare activities. "As a separate listed entity, Siemens Healthineers will have the entrepreneurial flexibility to actively shape its industry with a view to accelerating profitable growth and deliver return. It will also have direct access to the capital market, which will improve its ability to fund investment. Siemens will continue to actively support Siemens Healthineers as a majority shareholder."

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Automatic CLIA Analyzer
Shine i9000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more